Scholarlink

Objective <p>Non-high-density lipoprotein cholesterol, an aggregate marker of atherogenic lipoproteins, has been implicated in metabolic dysfunction and may predict non-alcoholic fatty liver disease risk. Our study investigated the association between non-high-density lipoprotein cholesterol and non-alcoholic fatty liver disease among people living with Human Immunodeficiency Virus on dolutegravir-based antiretroviral therapy in southwestern Uganda. We conducted a secondary analysis of data obtained from a cross-sectional study of 377 adults who had been on dolutegravir-based antiretroviral therapy for ≥ 12 months at Ruhoko Health Centre IV, southwestern Uganda.</p> Results <p>Of the 377 participants, 42(11.1%; 95CI: 8.3–14.8) had non-alcoholic fatty liver disease. We observed a significant association between high non-high-density lipoprotein cholesterol and non-alcoholic fatty liver disease; second tertile (aOR = 3.08, 95% CI: 1.06–8.99, <i>p</i> = 0.039) and third tertile (aOR = 4.46, 95% CI: 1.25–15.88, <i>p</i> = 0.021). At an optimal cut-off of ≥ 113.4 with a sensitivity of 69% and specificity of 48%, non-high-density lipoprotein cholesterol had a significant discriminative ability; AUC = 0.654(95%CI:0.561–0.747) to distinguish participants with from those without non-alcoholic fatty liver disease. Therefore, High non-high-density lipoprotein cholesterol is a potential predictor for non-alcoholic fatty liver disease.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Association between non-high-density lipoprotein cholesterol and non-alcoholic fatty liver disease among people living with HIV on dolutegravir-based antiretroviral therapy: A cross-sectional study in Southwestern Uganda

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月20日

查看全文
  • Charles Nkubi Bagenda,
  • Carol Nantongo,
  • Elastus Ssemwanga,
  • Michael Junior Mugisa,
  • Jesca Wafwoyo Akoth,
  • Daniel Nzaramba,
  • Rogers Kalyetsi,
  • Elizabeth A. John,
  • Jazira Tumusiime,
  • Blendar Ainebyoona,
  • Shadrach Omara,
  • Vicent Mwesigye,
  • Sylvia Achieng Lumumba,
  • Conrad Lubwama,
  • Benson Musinguzi,
  • Lucas Ampaire,
  • Rose Nassali,
  • Herbert Itabangi,
  • Lawrence Obado Osuwat,
  • Brian Ssenkumba,
  • Ronald Ouma Omolo

摘要

Objective

Non-high-density lipoprotein cholesterol, an aggregate marker of atherogenic lipoproteins, has been implicated in metabolic dysfunction and may predict non-alcoholic fatty liver disease risk. Our study investigated the association between non-high-density lipoprotein cholesterol and non-alcoholic fatty liver disease among people living with Human Immunodeficiency Virus on dolutegravir-based antiretroviral therapy in southwestern Uganda. We conducted a secondary analysis of data obtained from a cross-sectional study of 377 adults who had been on dolutegravir-based antiretroviral therapy for ≥ 12 months at Ruhoko Health Centre IV, southwestern Uganda.

Results

Of the 377 participants, 42(11.1%; 95CI: 8.3–14.8) had non-alcoholic fatty liver disease. We observed a significant association between high non-high-density lipoprotein cholesterol and non-alcoholic fatty liver disease; second tertile (aOR = 3.08, 95% CI: 1.06–8.99, p = 0.039) and third tertile (aOR = 4.46, 95% CI: 1.25–15.88, p = 0.021). At an optimal cut-off of ≥ 113.4 with a sensitivity of 69% and specificity of 48%, non-high-density lipoprotein cholesterol had a significant discriminative ability; AUC = 0.654(95%CI:0.561–0.747) to distinguish participants with from those without non-alcoholic fatty liver disease. Therefore, High non-high-density lipoprotein cholesterol is a potential predictor for non-alcoholic fatty liver disease.